Observational studyBMC nephrology2026

Patient characteristics and treatment efficacy after switching to hypoxia-inducible factor-prolyl hydroxylase inhibitors from erythropoiesis-stimulating agents in non-dialysis-dependent chronic kidney disease patients: the Reach-J CKD cohort study.

Kunihiro Yamagata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.